There can be few of us who have not encountered influenza either suffering at first hand or with friends and relatives or from the pages of medical history. It has been with us for a long time and the fact that it continues to remain a global threat is a reflection of the absence of a reliable antidote. The report of a significant and promising improvement in the fight to combat influenza infection is therefore of major scientific and public interest. The pages of Nature carried the news of the latest advances, which will also be of particular interest to glycobiologists (von Itzstein et aL, 1993b) . New inhibitors of the viral surface enzyme sialidase (neuraminidase) have been designed which are several orders of magnitude more potent than any described before and these are also effective in virus replication. They were designed on the basis of a detailed knowledge of the topography of the influenza sialidase active site and represent a triumph for the application of rational, computer-assisted drug design.
The presence of flu and its constant threat to mankind has been well documented in history from the ancient Greeks through to the Spanish, Asian and Hong Kong pandemics of this century. As it has been a regular cause of major mortality the search for possible cures has always been a focus of attention. However, the efforts of scientists to provide therapeutic and prophylactic treatments have met with only limited success even in recent times. Vaccines have been produced to epitopes derived from influenza virus A and B strains, the two strains commonly responsible for the pandemics in man, in an attempt to counter the ability of the virus to reassort its surface antigens and fool the immune system (Webster etaL, 1988; Corfield et al., 1992) . The vaccines have a limited effect and do not provide complete protection against infection. Part of the problem facing the design of vaccines is the great, naturally occurring potential for reasserting the antigenic forms of the main strains of influenza leading to new combinations which are not affected by the established vaccines of the time. An enormous reservoir of influenza genes is carried in birds, especially wild fowl, and this is believed to be a source of reassortant viruses which appear from time to time as pandemics in man and other animals. Chemical intervention to block influenza infection has been even less successful with only one drug, arnataHini*. and its derivatives, being used (Pinto et al., 1992) . The action of this drug is limited to influenza A, providing no protection against the B strain. In addition it has side effects and its use has been followed by the appearance of drug-resistant viral strains. As a result the search for alternative therapies has continued and has now returned to the concept of inhibiting viral surface © Oxford University Press molecules responsible for the processes of replication and infectivity.
Influenza virus recognizes and binds to glycoconjugates on cell surfaces through one of its surface proteins, haemagglutinin, but it also requires the action of a second surface protein, sialidase (neuraminidase) for effective infection and replication. The sialidases are a group of widely distributed grycohydrolases associated with pamogenicity and nutrition in microorganisms but with more specific functions in mammalian systems (Corfield et al., 1981; Corfield, 1992) . The viral sialidase shows a characteristic substrate specificity, allowing the release of newly synthesized virions from infected cells (Palese et al., 1974) , it also facilitates the movement of the virus to the mucosal cells by attacking the protective mucus layer at the mucosal surface (Klenk et aL, 1988; Corfield, 1992; Corfield etal., 1992) . These are typical properties for pathogenic microorganism sialidases (Corfield, 1992) and for this reason have been targets for inhibitor design. Attention has focused on the viral sialidases as several inhibitors have been described based on the naturally occurring 2-deoxy-2,3-di-dehydro-D-A r -acetyhieuraminic acid (Neu5Ac2en) which is thought to be a transition-state analogue for the sialosyl residue at the active site of the sialidase during the catalytic reaction (Miller etal, 1978) . Some analogues of Neu5Ac2en were tested as potential anti-viral agents nearly twenty years ago (Meindl et aL, 1974; Palese et aL, 1974) . However, the lack of specificity for viral sialidase inhibition over other sialidases, an apparent K\ in the range of 10~5-10~6 M and the rapid removal of these compounds from the circulation were found to be responsible for the lack of effective anti-viral action (Meindl et aL, 1974; Palese etal., 1974; Nohle etal., 1982; von Itzstein etal., 1993b) .
In addition to these inhibitor studies, a further powerful block of sialidase action has long been known due to the presence of 4-Oacetyl esters on glycosidically bound sialic acids (Schauer et al., 1968) . The presence of these esters effectively prevented the release of these sialic acids from glycoconjugates by sialidases of mammalian, bacterial and viral origin (Corfield et al., 1981) . Here hints were uncovered that the viral sialidases may be different as a low but significant release of these 4-0-acetylated sialic acids could be measured in contrast to other sialidases and substitution of the 4-0-acetyl by 4-0-methyl resulted in improved release by the viral enzymes (Beau et aL, 1980; Corfield etaL, 1981) . These results could not be interpreted in terms of the active site structure at the time but drew attention to the sialic acid 4-hydroxyl group as a site of particular importance for sialidase action.
A vital feature of the study of sialidase as a target for design of antiviral agents is the fact that the peptide sequences associated with the active sites of these enzymes are invariant between both A and B influenza strains and inhibition should thus be effective against all infections in man. The approach adopted by von Itzstein et al. (1993b) has been to investigate the molecular nature of the active site topography and enzyme inhibition of viral sialidase. The detailed crystal structure of the influenza virus sialidase molecule has been determined (Varghese et al., 1983 (Varghese et al., , 1991 and as a result the interaction of the enzyme with its substrates (sialogJycoconjugates), products (sialic acids) and inhibitors is known at a molecular, topographical level. This knowledge has been used in a rational study of Neu5Ac2en interaction with the viral protein and has resulted in the design of compounds with significantly greater potency. The geometry of the interaction of sialic acid (Neu5Ac) with the sialidase active site is similar to that of the inhibitor Neu5Ac2en. Analysis of the interactions of these two compounds at the active site revealed the existence of a pocket in the region of the 4-hydroxyl group. Two invariant glutamic acid residues at positions 119 and 227 were identified which did not interact directly with Neu5Ac or Neu5Ac2en but which were sufficiently close to form salt bridges with sialic acids modified at carbon 4 to include a positive charge. Accordingly 4-amino and 4-guanidino derivatives of Neu5Ac2en were synthesized (von Itzstein et al., 1993a) and tested (Holzer et al., 1993) . The measured crystal structures confirmed the computer predictions of salt bridges for both of these new inhibitors. In addition, the specificity of the inhibitors for the viral enzymes was dramatically increased, with apparent K± values of 10" 9 -10~1 0 M for the 4-guanidino derivative, which proved to be the most effective inhibitor in agreement with its interaction with both glutamic acid residues in the active site pocket. Inhibition of sialidase activity from bacteria, parainfluenza 2 virus and mammalian sources was up to 10* times less effective (von Itzstein et al, 1993b) . These findings are a very impressive demonstration of successful inhibitor design.
The results suggest the intriguing possibility that the 'pocket' identified in the influenza sialidase is a novel viral feature. Evolution of the sialidases in other microorganisms, including parainfluenza 2 virus has apparently resulted in a modification of this pocket. DNA sequence data derived from different microorganism sialidases has shown the conservation of common peptide features (e.g. Rome et al., 1991) but translation of this information into active site structure is not yet available and the significance of the conserved features remains speculative. Progress in determining the structure of the active site, of viral sialidases has outstripped that for other microorganism enzymes (Taylor, 1993) , while the mammalian sialidases remain very much in their infancy. As a result a direct answer to these questions must wait a little longer.
The impressive success in the design and synthesis of these new sialidase inhibitors is the first step in the investigation of their efficiency as inhibitors of viral replication and infection. The finding of a high binding affinity of the 4-amino and 4-guanidino derivatives of Neu5Ac2en to the influenza sialidase augered well for successful intervention in the disease process in contrast to the earlier studies. Testing of the derivatives in" tissue culture and animal models of influenza infection gave positive results and provided direct demonstration that virus replication can be inhibited by these compounds. Influenza A and B virus plaque formation in cultured MDCK cells was inhibited by both 4-amino-and 4-guanidino-Neu5Ac2en with the guanidino derivative being more potent as expected. 4-Guanidino-Neu5Ac2en prevented influenza virus replication in mice and ferrets infected with inflnen7a. and was 100-to 1000-fold more effective than amantaHini» and its analogues. Testing of alternative routes for the administration of the inhibitors confirmed that intranasal application is most effective and supports a respiratory cell surface location for virus replication and an extracellular role for sialidase in the process.
The success of these biological experiments is most encouraging for the final step to human disease and represents the most significant advance in the development of a treatment for influenza infection so far. However, the magnitude of this final step to treatment of human infection must not be underestimated in spite of the striking success of the current report and direct 'proof of the pudding' is still required.
These latest advances leave us with several unanswered questions which go to the heart of the whole problem of antiviral agents. One of the major problems of the influenza vaccine programme has been the ability of the virus to reassort under pressure and respond wim new antigenic variants. In the same way resistant mutants to amantadine have also been detected. At present there is no indication whether a resistant sialidase, perhaps with a mutant 'pocket', will appear in the face of exposure to 4-guanidino-and 4-amino-Neu5Ac2en. Preliminary results to test for the appearance of such resistance have so far not shown any evidence for this type of change (von Itzstein et al., 1993b ) but more time is required to test this fully. Other questions regard the existence of the 'pocket' in viral sialidases and why this should be preserved, especially as prevailing evidence suggests that the evolution of sialidases in other viruses, microorganisms and animals has progressed without this feature. The carbon 4-hydroxyl position of sialic acid is clearly a special location in sialidases in general and the reasons for this have also not yet been probed satisfactorily.
The key question of the moment is how will human influenza respond to me use of these inhibitors. Once again we will have to wait to see the results of ongoing research. Although the history of influenza is a very long one we now seem to be tantalizingly close to real progress. The days of influenza virus may at last be numbered thanks to the successful application of rational computer-assisted drug design to this long standing public health problem in a major area of glycobiology.
Glycobiology provides a challenging research area in which the integrity of complex carbohydrates in glycoproteins and glycolipids is maintained by a balance between the actions of glycosyltransferases and glycohydrolyases. In turn, the biological actions of the many diverse glycoconjugates that result serve to maintain a wide range of cellular processes. The importance of the roles for glycoconjugates increases the significance of the fact that glycoconjugate integrity can be altered by ingestion of alcohol, and such alterations may, in turn, alter the integrity of a significant number of physiologically important systems. Thus, alcohol research provides an opportunity for a wide range of new glycobiology research initiatives that can help identify possible underlying mechanisms associated with alcohol-induced tissue damage. This brief review illustrates several types of published results to indicate the breadth of opportunity available.
A beginning of curiosity
One of the best indicators that alcohol has an almost inescapable action on glycoconjugates is in the world-wide recognition that carbohydrate-deficient transferrin (CDT) in plasma is a sensitive and reliable marker of alcohol abuse (e.g. Stibler and Borg, 1986; Stibler et al., 1986) . The plasma levels of CDT appear to be not associated with the degree of liver injury, but reflect primarily the level of daily alcohol consumption in alcoholic patients (Stibler and Hultcrantz, 1987) . The main alcohol-induced impairment is in the carbohydrate residues attached at positions 413 and 611 in the transferrin (Petren et al., 1987) , including decreases in galactose, A'-acetylglucosamine as well as sialic acid. Enzyme activities responsible for these alcohol-induced changes may include both increased sialidase and decreased sialyltransferase (Ghosh etal, 1993; Mihas and Tavassoli, 1993) . By monitoring plasma CDT levels, clinicians are able to determine the success of treatment interventions in maintaining abstinence of a patient Such a tactic has utility for clinical practice, but it also stands as a clear invitation to basic researchers to develop new understanding of the scope and intensity of alcohol-induced changes in glycobiology and the possible mechanisms whereby alcohol exerts its wide range of effects on tissue functions.
Decreased amounts of galactose (16%) and sialic acid (10%) in the membranes of erythrocytes of alcoholics resemble those of the CDT phenomenon, and they may be due either to increased hydrolysis or to decreased synthesis of glycoconjugates (Stibler and Borg, 1982) . The 16% decrease in galactose represents an absolute decrease in mass that was three times that of sialic acid. Erythrocyte gangliosides (especially GM3 and GD3) are also decreased by chronic alcohol intake, and their levels return to normal with prolonged abstinence (Beyer et al., 1990) . The biological significance of these alcohol-induced changes is indicated by the fact that elimination of 10% of the sialic acid content of erythrocytes causes rapid elimination of the cells from the circulation, decreases electrophoretic mobility and increases agglutinability and haemolysis.
The breadth of opportunity
The past decade has provided numerous examples of alcoholinduced impairments in the integrity of glycoconjugate metabolism in liver. They included increased endogenous acceptors for galactosyltransferase (Femandez-Briera et aL, 1990) , impaired receptor-mediated endocytosis (Tuma et aL, 1981; Matsuda etal., 1988) . How does ingested alcohol impair cellular glycosyltransferases? Evidence of a parallel alcoholinduced impairment of glycoconjugates in brain included a double amount of exposed galactose and Af-acetylgalactosamine in synaptic membranes of mice (Goldstein etal., 1983) , decreased contents of gangliosides in mouse brain (Klemm et al., 1988) and decreased contents of sialic acid in synaptosomal glycolipids and glycoproteins (Stibler etal., 1985) . Effects of alcohol on the developing fetus include inhibition of embryogenesis, cell migration and differentiation, and these were reviewed recently in the context of the role of gangliosides in the structure and function of cell membranes (Hungund and Mahadik, 1993) . Do altered cell surface glycoconjugates mediate the teratogenic effects of alcohol? Alcohol consumption is associated with a lower occurrence of cardiovascular mortality. Is this phenomenon linked to altered secretion of glycolipoproteins by liver, to less glycoconjugate-mediated adhesion at vascular inflammatory sites, or to an alcohol-induced impairment of glycoconjugate support of thombus formation? In Le(a~b-) men, genetically at high risk for ischaemic heart disease, alcohol consumption seemed to be especially protective (Hein etal, 1993) . Was this linked to an alcohol-mediated change in glycoconjugates? Finally, an ethanol-induced impairment in the synthesis and secretion of the glycoprotein of gastric mucus has been indicated (Slomiany et al, 1985) . Is this a mechanism for alcohol-induced impairment of intestinal integrity? All of these alcohol-induced alterations provide evidence of the ability of ingested alcohol to unleash processes,
